These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 35436669)
1. Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors. Lei H; Wang X; Zhao G; Li T; Cui Y; Wu H; Yang J; Jiang N; Zhai X Eur J Med Chem; 2022 Jun; 236():114307. PubMed ID: 35436669 [TBL] [Abstract][Full Text] [Related]
2. Novel imidazo[1,2-a]pyridine derivatives as potent ATX allosteric inhibitors: Design, synthesis and promising in vivo anti-fibrotic efficacy in mice lung model. Lei H; Li Z; Li T; Wu H; Yang J; Yang X; Yang Y; Jiang N; Zhai X Bioorg Chem; 2022 Mar; 120():105590. PubMed ID: 34998121 [TBL] [Abstract][Full Text] [Related]
3. Hybrid imidazo[1,2-a]pyridine analogs as potent ATX inhibitors with concrete in vivo antifibrosis effect. Li T; Lei H; Yang J; Cao Z; Yang Y; Liu Z; Sun R; Yang X; Zhai X Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200171. PubMed ID: 35661405 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and anti-fibrosis evaluation of imidazo[1,2-a]pyridine derivatives as potent ATX inhibitors. Chen Y; Lei H; Li T; Cui Y; Wang X; Cao Z; Wu H; Zhai X Bioorg Med Chem; 2021 Sep; 46():116362. PubMed ID: 34428714 [TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of tetrahydropyrido[4,3-d]pyrimidine derivatives as novel ATX and EGFR dual inhibitors. Jing T; Miao X; Jiang F; Guo M; Xing L; Zhang J; Zuo D; Lei H; Zhai X Bioorg Med Chem; 2018 May; 26(8):1784-1796. PubMed ID: 29496411 [TBL] [Abstract][Full Text] [Related]
6. Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model. Lei H; Cao Z; Wu H; Li T; Wang X; Chen Y; Ma E; Sun L; Zhai X Eur J Med Chem; 2022 Jan; 227():113951. PubMed ID: 34742015 [TBL] [Abstract][Full Text] [Related]
7. Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors. Joncour A; Desroy N; Housseman C; Bock X; Bienvenu N; Cherel L; Labeguere V; Peixoto C; Annoot D; Lepissier L; Heiermann J; Hengeveld WJ; Pilzak G; Monjardet A; Wakselman E; Roncoroni V; Le Tallec S; Galien R; David C; Vandervoort N; Christophe T; Conrath K; Jans M; Wohlkonig A; Soror S; Steyaert J; Touitou R; Fleury D; Vercheval L; Mollat P; Triballeau N; van der Aar E; Brys R; Heckmann B J Med Chem; 2017 Sep; 60(17):7371-7392. PubMed ID: 28731719 [TBL] [Abstract][Full Text] [Related]
8. An updated patent review of autotaxin inhibitors (2017-present). Tan Z; Lei H; Guo M; Chen Y; Zhai X Expert Opin Ther Pat; 2021 May; 31(5):421-434. PubMed ID: 33342311 [TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Preliminary Bioactivity Evaluation of 2,7-Substituted Carbazole Derivatives as Potent Autotaxin Inhibitors and Antitumor Agents†. Wang W; Zhao F; Zhao Y; Pan W; Cao P; Wu L; Wang Z; Zhao X; Zhao Y; Wang H Anticancer Agents Med Chem; 2019; 19(2):256-264. PubMed ID: 30173652 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, docking and biological evaluation of 4-phenyl-thiazole derivatives as autotaxin (ATX) inhibitors. Balupuri A; Lee DY; Lee MH; Chae S; Jung E; Kim Y; Ryu J; Kang NS Bioorg Med Chem Lett; 2017 Sep; 27(17):4156-4164. PubMed ID: 28743508 [TBL] [Abstract][Full Text] [Related]
12. Discovery of Novel Indole-Based Allosteric Highly Potent ATX Inhibitors with Great Lei H; Guo M; Li X; Jia F; Li C; Yang Y; Cao M; Jiang N; Ma E; Zhai X J Med Chem; 2020 Jul; 63(13):7326-7346. PubMed ID: 32479084 [TBL] [Abstract][Full Text] [Related]
13. Structure guided design of potent indole-based ATX inhibitors bearing hydrazone moiety with tumor suppression effects. Lei H; Li C; Yang Y; Jia F; Guo M; Zhu M; Jiang N; Zhai X Eur J Med Chem; 2020 Sep; 201():112456. PubMed ID: 32535330 [TBL] [Abstract][Full Text] [Related]
14. Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells. Banerjee S; Norman DD; Lee SC; Parrill AL; Pham TC; Baker DL; Tigyi GJ; Miller DD J Med Chem; 2017 Feb; 60(4):1309-1324. PubMed ID: 28112925 [TBL] [Abstract][Full Text] [Related]
15. Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis. Jiang N; Zhou Y; Zhu M; Zhang J; Cao M; Lei H; Guo M; Gong P; Su G; Zhai X Eur J Med Chem; 2020 Feb; 187():111904. PubMed ID: 31806537 [TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of ATX inhibitors via modeling, synthesis and biological evaluation. Balupuri A; Lee MH; Chae S; Jung E; Yoon W; Kim Y; Son SJ; Ryu J; Kang DH; Yang YJ; You JN; Kwon H; Jeong JW; Koo TS; Lee DY; Kang NS Eur J Med Chem; 2018 Mar; 148():397-409. PubMed ID: 29477073 [TBL] [Abstract][Full Text] [Related]
17. Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme. Gerokonstantis DT; Nikolaou A; Magkrioti C; Afantitis A; Aidinis V; Kokotos G; Moutevelis-Minakakis P Bioorg Med Chem; 2020 Jan; 28(2):115216. PubMed ID: 31864778 [TBL] [Abstract][Full Text] [Related]